Wolverine Stack

BPC-157 + TB-500 blend — a 1:1 dual-peptide combination of BPC-157 (Body Protection Compound-157, a 15-amino-acid pentadecapeptide derived from human gastric juice) and TB-500 (Thymosin Beta-4 fragment, a 43-amino-acid peptide involved in tissue repair and cell migration).

Profile · 01

Overview

BPC-157 + TB-500 is a 1:1 dual-peptide blend combining BPC-157 (Body Protection Compound-157, a 15-amino-acid pentadecapeptide derived from human gastric juice) and TB-500 (Thymosin Beta-4 fragment, a 43-amino-acid peptide involved in tissue repair and cell migration). This combination targets complementary healing pathways — BPC-157 for cytoprotective and anti-inflammatory activity, and TB-500 for cell migration and angiogenesis. Neither peptide is FDA-approved for any indication. Evidence is drawn primarily from preclinical models and early clinical observations. This protocol presents a once-daily subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal

Support tissue repair, wound healing, and recovery from musculoskeletal injuries

Protocol

Suggested daily protocol with a loading phase and maintenance phase over 8 weeks.

Typical daily range

600–1000 mcg total once daily (300–500 mcg each peptide)

Start

600 mcg total daily (300 mcg each); increase to 800 mcg at Week 3

Target

600–800 mcg total daily by Weeks 3–8

Frequency

Once per day (subcutaneous)

Cycle Length

8–12 weeks; optional extension to 16 weeks

Timing

Any consistent time; rotate injection sites

Route

Subcutaneous

Cycle

8–12 weeks on, 4 weeks off

Inject once daily subcutaneously using the largest practical dilution to maintain measurement accuracy. BPC-157 and TB-500 address complementary healing pathways — cytoprotective and anti-inflammatory (BPC-157) alongside cell migration and angiogenesis (TB-500). Dosing extrapolates from preclinical models; human clinical validation remains limited.

Dose progression

Weeks 1–2

600 mcg (300 mcg each)

Weeks 3–4

800 mcg (400 mcg each)

Weeks 5–8

600 mcg (300 mcg each)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Profile · 03

Videos

Science · 01

How Wolverine Stack works.

BPC-157 corresponds to a partial sequence of human gastric juice protein and modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition. TB-500 is a synthetic fragment of Thymosin Beta-4 that facilitates cell migration and cytoskeletal remodeling by binding to actin and promoting cell mobilization to injury sites. Together, the blend addresses wound repair through both cytoprotective signaling (BPC-157) and structural cell migration (TB-500). Animal models report accelerated healing of tendon, ligament, muscle, and soft tissue injuries with both peptides. A case series noted improved outcomes at higher combined doses intra-articularly, but systemic subcutaneous protocols typically use the lower ranges described above. Large-scale controlled human efficacy data for the combination remain unavailable.

Science · 02

Effects

Observations from clinical or preclinical literature.

May support accelerated healing of tendons, ligaments, muscles, and soft tissue injuries (animal data)

BPC-157 demonstrates gastroprotective and anti-inflammatory properties in preclinical settings

TB-500 promotes wound healing and may reduce scarring through enhanced cell migration

Both peptides are generally well tolerated with occasional mild injection-site reactions (redness, itching)

No significant toxicity documented up to high doses in animal studies

Long-term human safety and efficacy remain under investigation

Science · 03

Caution

Individuals with active cancer or a history of cancer should avoid use due to pro-angiogenic properties of both peptides

Not recommended during pregnancy or breastfeeding (no safety data available)

Use with caution if taking anticoagulants or medications affecting blood clotting

Both peptides are prohibited in competitive sports by WADA

Consult a healthcare provider before use if you have any chronic medical conditions

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Zinc

Supports wound healing and immune function; commonly depleted in tissue injury.

Vitamin C

Essential cofactor for collagen synthesis and tissue repair.

Magnesium

Supports enzymatic processes involved in tissue recovery.

Omega-3 fatty acids

Support anti-inflammatory pathways complementary to the blend's mechanisms.

Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Adequate protein intake (1.6–2.2 g/kg body weight) to support tissue regeneration

Appropriate rehabilitation protocols for injuries; balance activity and rest

Prioritize sleep (7–9 hours nightly) and manage stress to enhance natural healing processes

Consult qualified healthcare providers for injury-specific rehabilitation guidance

Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

Pain levels and functional mobility — monitor changes in the target area to gauge healing response
Inflammation markers (subjective swelling, redness, heat) — track daily to identify trends
Sleep quality and recovery perception — poor sleep impairs healing; track to ensure adequate rest
Injection-site reactions — note any redness, swelling, or discomfort to guide site rotation

Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

CRP (C-Reactive Protein)

General inflammation marker; track before and during protocol.

ESR (Erythrocyte Sedimentation Rate)

Secondary inflammation marker to corroborate CRP trends.

CBC (Complete Blood Count)

Monitor overall health and rule out underlying conditions.

CMP (Comprehensive Metabolic Panel)

Assess liver and kidney function during peptide use.

Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length

Vial size

Bac. water

Syringe

Vials

0 × 20 mg each…

Syringes

Bac. water

0 mL

Swabs

02 per syringe

Calculators · 02

Dose Calculator

Vial

Bac. water

Syringe

Dose

Concentration

0mcg/mL

Volume per dose

0mL

…

Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

Allow vial to reach room temperature for 15–20 minutes before reconstitution.
Draw the chosen bacteriostatic water volume with a sterile syringe.
Inject slowly down vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use within 30 days; discard any unused solution after 30 days.

Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to dry

Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue

Do not aspirate for subcutaneous injections; inject slowly and steadily

Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms, flank) to avoid lipohypertrophy

Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized

Store at room temp in dry, dark conditions; minimize moisture exposure.

Reconstituted

Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.

Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container

Rotate injection sites (abdomen, thighs, upper arms, flank) to reduce local irritation

Inject slowly; wait a few seconds before withdrawing the needle

Apply gentle pressure post-injection; do not rub the site

Document daily dose and site rotation to maintain consistency

Both BPC-157 and TB-500 are not approved for routine human use and are banned in competitive sports

Human data are preliminary; clinical decisions should involve qualified healthcare providers

Reference · 02

References

Journal of Pharmacological Sciences
Klicek R et al., "BPC-157 promotes colocutaneous fistula healing via NO-system modulation (rat model)".
https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_article
Current Pharmaceutical Design (PMC)
Sikiric P et al., "BPC-157 stable gastric pentadecapeptide: novel therapy for wound healing and tissue repair".
https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/
Annals of the New York Academy of Sciences
Goldstein AL et al., "Thymosin β4: actin-sequestering protein in wound healing and tissue regeneration".
https://pubmed.ncbi.nlm.nih.gov/15809501/
FASEB Journal
Malinda KM et al., "Thymosin β4 accelerates wound healing".
https://pubmed.ncbi.nlm.nih.gov/10473525/
Life Sciences
Seiwerth S et al., "BPC-157 and standard angiogenic growth factors: gastrointestinal tract healing and beyond".
https://pubmed.ncbi.nlm.nih.gov/29990514/
WHO (NCBI Bookshelf)
"Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings (2016)".
https://www.ncbi.nlm.nih.gov/books/NBK390474/
Johns Hopkins Arthritis Center
"How to give a subcutaneous injection (patient education resource)".
https://www.hopkinsarthritis.org/patient-corner/how-to-give-a-subcutaneous-injection/
CDC
"Vaccine administration: subcutaneous route (angle/site; no aspiration)".
https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
Subcutaneous Drug Injection Review (PMC)
"Pharmacologic considerations of the subcutaneous route".
https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/